Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant expenditures to private-sector innovations. Second, we take advantage of idiosyncratic rigidities in the rules governing NIH peer review to generate exogenous variation in funding across research areas. Our results show that NIH funding spurs the development of private-sector patents: a $10 million boost in NIH funding leads to a net increase of 2.3 patents. Though valuing patents is difficult, we report a range of estimates for the private value of these patents using different approaches.
-
-
Copy CitationPierre Azoulay, Joshua S. Graff Zivin, Danielle Li, and Bhaven N. Sampat, "Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules," NBER Working Paper 20889 (2015), https://doi.org/10.3386/w20889.Download Citation
-
Non-Technical Summaries
- An additional $10 million in NIH funding generates 3.1 additional private-sector patents in the research area that receives...
Published Versions
Pierre Azoulay & Joshua S Graff Zivin & Danielle Li & Bhaven N Sampat, 2019. "Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules," The Review of Economic Studies, vol 86(1), pages 117-152. citation courtesy of 
Related
Working Groups
More from the NBER
In addition to working papers, the NBER disseminates affiliates’ latest findings through a range of free periodicals — the NBER Reporter, the NBER Digest, the Bulletin on Health, and the Bulletin on Entrepreneurship — as well as online conference reports, video lectures, and interviews.
